Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.
Our library stands out due to several important features:
partner
Reaxense
upacc
P34981
UPID:
TRFR_HUMAN
Alternative names:
Thyroliberin receptor
Alternative UPACC:
P34981; Q2M339
Background:
The Thyrotropin-releasing hormone receptor, also known as the Thyroliberin receptor, plays a pivotal role in the endocrine system. It is a G-protein-coupled receptor that activates the phosphatidylinositol-calcium-protein kinase C pathway upon binding with thyrotropin-releasing hormone (TRH). This receptor is crucial for the regulation of thyroid hormone secretion.
Therapeutic significance:
Linked to Hypothyroidism, congenital, non-goitrous, 7, a disorder characterized by sub-optimal thyroid hormone secretion due to insufficient stimulation by thyrotropin, the Thyrotropin-releasing hormone receptor's study could lead to novel treatments for thyroid-related conditions. Understanding its function and the genetic variants affecting it offers a pathway to targeted therapies.